Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,435.00
Bid: 1,454.00
Ask: 1,456.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.138%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,435.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Declaration

3 Feb 2017 13:30

RNS Number : 0142W
Indivior PLC
03 February 2017
 

Indivior PLC (the 'Company') - Director Declaration

The Board of Indivior PLC announces that Cary Claiborne has stepped down from his role as Chief Financial Officer in order to pursue other opportunities. The Board of Indivior PLC has appointed Mark Crossley to succeed Cary as CFO.

Mark is currently Chief Strategy Officer of Indivior and was previously Finance Director of the Reckitt Benckiser Pharmaceuticals division prior to the demerger.

Cary will assist with the transition over the coming weeks ahead of the scheduled release of Full Year Results on February 22. As part of the transition, we expect that Cary will step down from the Board and will be replaced by Mark in due course.

Shaun Thaxter, Chief Executive Officer of Indivior PLC, paid tribute to Cary's contribution to the Company during his tenure as Chief Financial Officer from 2014-2017:

"Cary joined us to bring public company experience to the demerger process and the establishment of Indivior as a separate, independent, listed company. He has managed through the complexities of the demerger and separation from Reckitt Benckiser, and the set-up of Indivior, including establishing corporate reporting, internal audit, tax, treasury and external audit; he has also overseen the global implementation of SAP. Throughout these many changes, the Company has delivered strong financial performance and provided transparency to our shareholders. We thank Cary for his many contributions to the successful evolution of Indivior so far and wish him well for the next phase of his career."

Mark was appointed to his current position as Chief Strategy Officer in October 2014. He joined the Company in 2012 as the Global Finance Director with responsibilities for Finance, Information Systems and Procurement. Prior to joining Indivior, Mark spent 13 years at Procter & Gamble in various finance leadership roles including Corporate Portfolio, Strategic and Business Planning (Female Beauty), as well as multiple roles in Corporate Treasury and its Baby Care division. He also enjoyed an eight year career with various operational and staff assignments in the United States Coast Guard. Mark graduated from the United States Coast Guard Academy with a BS in Management and Economics, and from Boston College with an MBA. He is a National Association of Corporate Directors Leadership Fellow.

Thaxter continued, "We welcome Mark Crossley to the role of Chief Financial Officer and look forward to benefiting from his experience and knowledge of the business in leading the finance function into the next phase of Indivior's development."

The Company confirms there is no further information to be disclosed pursuant to LR 9.6.13 in connection with Mark Crossley's appointment.

 

Media Contacts

Tulchan Communications

+44 207 353 4200

Stephen Malthouse

Jonathan Sibun

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCOKNDKNBKDCBK
Date   Source Headline
23rd May 20237:00 amRNSUS FDA Approves OPVEE
12th May 20232:56 pmRNSHolding(s) in Company
10th May 20233:30 pmRNSDirector/PDMR Shareholding
10th May 202312:00 pmRNSBlock listing Interim Review
10th May 20238:51 amRNSHolding(s) in Company
4th May 20232:48 pmRNSResult of AGM
27th Apr 202312:00 pmRNS1st Quarter Results
25th Apr 20232:30 pmRNSIndivior to Participate in Conference
25th Apr 20239:26 amRNSHolding(s) in Company
20th Apr 20238:43 amRNSHolding(s) in Company
18th Apr 20238:09 amRNSHolding(s) in Company
17th Apr 20234:25 pmRNSHolding(s) in Company
11th Apr 20232:00 pmRNSNotice of Q1 Results
6th Apr 202312:24 pmRNSHolding(s) in Company
3rd Apr 20239:35 amRNSTotal Voting Rights
30th Mar 20232:37 pmRNSHolding(s) in Company
28th Mar 20233:21 pmRNSHolding(s) in Company
27th Mar 202311:42 amRNSAnnual Financial Report
24th Mar 20232:30 pmRNSDirector/PDMR Shareholding
23rd Mar 202310:02 amRNSBlock Listing of Shares
22nd Mar 20233:00 pmRNSDirector/PDMR Shareholding
16th Mar 20232:30 pmRNSDirector/PDMR Shareholding
15th Mar 20232:30 pmRNSDirector/PDMR Shareholding
13th Mar 20234:04 pmRNSDirector/PDMR Shareholding
13th Mar 20232:36 pmRNSHolding(s) in Company
8th Mar 20239:42 amRNSDirector/PDMR Shareholding
6th Mar 20234:00 pmRNSDirector/PDMR Shareholding
6th Mar 202310:21 amRNSHolding(s) in Company
2nd Mar 20231:56 pmRNSIndivior Completes Opiant Transaction
2nd Mar 20238:43 amRNSCompletion of Share Repurchase Program
1st Mar 20234:35 pmRNSDirector/PDMR Shareholding
1st Mar 202310:09 amRNSTotal Voting Rights
1st Mar 20237:00 amRNSTransaction in Own Shares
28th Feb 20237:00 amRNSTransaction in Own Shares
27th Feb 20234:18 pmRNSHolding(s) in Company
27th Feb 20237:00 amRNSTransaction in Own Shares
24th Feb 20237:00 amRNSTransaction in Own Shares
23rd Feb 20237:00 amRNSTransaction in Own Shares
22nd Feb 20234:52 pmRNSHolding(s) in Company
22nd Feb 20237:00 amRNSTransaction in Own Shares
21st Feb 202312:15 pmRNSIndivior to Participate in Conference
21st Feb 20239:09 amRNSHolding(s) in Company
21st Feb 20237:00 amRNSTransaction in Own Shares
20th Feb 20237:00 amRNSTransaction in Own Shares
17th Feb 20237:00 amRNSTransaction in Own Shares
16th Feb 20233:00 pmRNSSID & Chair of Remuneration Committee
16th Feb 20237:00 amRNSFinal Results
16th Feb 20237:00 amRNSTransaction in Own Shares
15th Feb 20237:00 amRNSTransaction in Own Shares
14th Feb 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.